News

Matthew J. Matasar, MD, discusses the ways to improve on the combination of R-CHOP in patients with diffuse large B-Cell lymphoma.

Part 2 of the phase 1/2 trial investigating LUT014, a topical agent for radiation-induced dermatitis in patients with breast cancer, completed its enrollment of 20 patients.

In an interview with Targeted Oncology, Shawn Dason, MD, discussed existing disparities in prostate cancer, the impact of the COVID-19 pandemic on the issue, and achieving health equity for patients with prostate cancer in the future.

Efficacy and toxicity of standard four dose nivolumab and ipilimumab induction therapy in melanoma to be likely driven by the first 2 doses as demonstrated in the Adaptively Dosed ImmunoTherapy Trial.

MARCH study in patients with relapsed/refractory multiple myeloma confirms the results of the STORM study and demonstrates positive overall response rates.

The PROPHETIC trial of a predictive diagnostic analysis platform expanded to a new site at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

According to 5-year survival data from the BILCAP study, capecitabine stands up to observation as a treatment strategy for patient with biliary tract cancer.

The FDA has granted orphan drug designation to serplulimab for the treatment of patients with small cell lung cancer.

Several notable trials in colorectal cancer suggest a shift in treatment management, especially in the length of treatment with immunotherapies.

Oncologists from Florida Cancer Specialists & Research Institute recently participated in the FLASCO Fellow & Resident Educational Training Program.

Using combination treatments in the concurrent setting with chemotherapy, radiation therapy, or small molecule oncogene and pathway inhibitors may yield positive data in one setting but not another.

Results from the BIONIKK study confirm that response to immune checkpoint inhibitor monotherapy or combination therapy as well as to VEGFR tyrosine kinase inhibitor therapy is different depending on the characteristics of the tumor and its microenvironment.

Leuprolide 42 mg injection emulsion for the treatment of adult patients with advanced prostate cancer has launched in the United States.

Results from the phase 3 I/ONTAK trial demonstrated anti-tumor activity in the treatment of persistent or recurrent CTCL

Tracy Rose, MD, discusses the promising outlook of the current bladder cancer space.

FDA fast track designation has been granted to a novel agent, DT2216, for the treatment of patient with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.

In an interview with Targeted Oncology, Viktor Grünwald, MD, discussed the newest updates and advances in RCC and what the current space looks like.

Matthew T. Campbell, MD, discusses the unmet needs for patients with renal cell carcinoma and sarcomatoid dedifferentiation.

An application seeking the approval of a new indication for the combination of ibrutinib, bendamustine, and rituximab in adult patients with previously untreated mantle cell lymphoma has been submitted.

Regulatory approval has been granted for Guardant360 in Japan and will offer tumor mutation profiling and companion diagnostics for therapies in patients with solid tumors which have KRAS G12C or MSI-H status.

The phase 1 ADVANCED-1 trial of the biologic immunopotentiator agent TARA-002 began dosing patients with non-muscular invasive bladder cancer.

Rajneesh Nath, MD, discusses what is in store regarding treatment for elderly patients with relapsed/refractory acute myeloid leukemia.

A phase 1 trial which will evaluate the safety and efficacy of chimeric antigen receptor T-cell therapy in ovarian cancer has begun.

The FDA has granted fast track designation to PRGN-3006 for the treatment of patients with relapsed or refractory cute myeloid leukemia .

The phase 1/2 TakeAim Leukemia study exploring emavusertib in patients with acute myeloid leukemia and myelodysplastic syndrome has been halted by the FDA pending more safety and efficacy data.

Andreana Holowatyj discusses the key takeaway for community oncologists about early-onset appendiceal cancer.

In a small safety run-in analysis, no safety concerns were reported with frontline pelareorep in patients with metastatic colorectal cancer.

Steve M. Albelda, MD, discusses the successes and downfalls of chimeric antigen receptor T cells in solid tumor research.

AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.